Traws Pharma Inc (TRAW) recently have taken one step ahead with the beta value of 0.91

Traws Pharma Inc (NASDAQ: TRAW) flaunted slowness of -7.64% at $11.61, before settling in for the price of $12.57 at the close. Taking a more long-term approach, TRAW posted a 52-week range of $4.06-$19.94.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -2.76%. Meanwhile, its Annual Earning per share during the time was 58.67%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -586.00%. This publicly-traded company’s shares outstanding now amounts to $3.03 million, simultaneously with a float of $2.28 million. The organization now has a market capitalization sitting at $32.45 million. At the time of writing, stock’s 50-day Moving Average stood at $5.24, while the 200-day Moving Average is $11.01.

Traws Pharma Inc (TRAW) Ownership Facts and Figures

Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Traws Pharma Inc industry. Traws Pharma Inc’s current insider ownership accounts for 24.59%, in contrast to 1.35% institutional ownership.

Traws Pharma Inc (TRAW) Earnings and Revenue Records

Traws Pharma Inc’s EPS decrease for this current 12-month fiscal period is -586.00% and is forecasted to reach -35.52 in the upcoming year.

Traws Pharma Inc (NASDAQ: TRAW) Trading Performance Indicators

Let’s observe the current performance indicators for Traws Pharma Inc (TRAW). It’s Quick Ratio in the last reported quarter now stands at 1.07. The Stock has managed to achieve an average true range (ATR) of 1.48. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 141.07.

In the same vein, TRAW’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -141.35, a figure that is expected to reach -9.55 in the next quarter, and analysts are predicting that it will be -35.52 at the market close of one year from today.

Technical Analysis of Traws Pharma Inc (TRAW)

Now, what If we examine the latest scores posted by [Traws Pharma Inc, TRAW]. During the last 5-days, its volume was better the volume of 0.12 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 48.78% While, its Average True Range was 2.03.

Raw Stochastic average of Traws Pharma Inc (TRAW) in the period of the previous 100 days is set at 49.09%, which indicates a major rise in contrast to 47.24% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 383.42% that was higher than 164.24% volatility it exhibited in the past 100-days period.